US20080076163A1 - L-cysteine-producing microorganism and a method for producing L-cysteine - Google Patents
L-cysteine-producing microorganism and a method for producing L-cysteine Download PDFInfo
- Publication number
- US20080076163A1 US20080076163A1 US11/070,084 US7008405A US2008076163A1 US 20080076163 A1 US20080076163 A1 US 20080076163A1 US 7008405 A US7008405 A US 7008405A US 2008076163 A1 US2008076163 A1 US 2008076163A1
- Authority
- US
- United States
- Prior art keywords
- cysteine
- gene
- activity
- escherichia
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title claims abstract description 165
- 239000004201 L-cysteine Substances 0.000 title claims abstract description 72
- 235000013878 L-cysteine Nutrition 0.000 title claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 title description 15
- 244000005700 microbiome Species 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 110
- 230000000694 effects Effects 0.000 claims abstract description 97
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 claims abstract description 89
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 claims abstract description 87
- 241000588722 Escherichia Species 0.000 claims abstract description 51
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 102000034356 gene-regulatory proteins Human genes 0.000 claims abstract description 18
- 108091006104 gene-regulatory proteins Proteins 0.000 claims abstract description 18
- VZXPDPZARILFQX-BYPYZUCNSA-N O-acetyl-L-serine Chemical compound CC(=O)OC[C@H]([NH3+])C([O-])=O VZXPDPZARILFQX-BYPYZUCNSA-N 0.000 claims abstract description 10
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 241000588724 Escherichia coli Species 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 108091022908 Serine O-acetyltransferase Proteins 0.000 claims description 31
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000001851 biosynthetic effect Effects 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 abstract description 3
- 239000013612 plasmid Substances 0.000 description 54
- 101150029709 cysM gene Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 31
- 239000002609 medium Substances 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 20
- 235000018417 cysteine Nutrition 0.000 description 20
- 101150055530 sat gene Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 239000013611 chromosomal DNA Substances 0.000 description 18
- 239000000284 extract Substances 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 101150028326 CD gene Proteins 0.000 description 11
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 10
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 10
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108020005091 Replication Origin Proteins 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 101150042538 malY gene Proteins 0.000 description 7
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 229960003067 cystine Drugs 0.000 description 5
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000219195 Arabidopsis thaliana Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101100498063 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cysB gene Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 description 4
- 101150111114 cysE gene Proteins 0.000 description 4
- 101150094831 cysK gene Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 101150117293 metC gene Proteins 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 4
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 4
- 229960001327 pyridoxal phosphate Drugs 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 101150099895 tnaA gene Proteins 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 101100075914 Escherichia coli (strain K12) malY gene Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 101150112941 cysK1 gene Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 101100076641 Bacillus subtilis (strain 168) metE gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101150057540 aar gene Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- NNLOHLDVJGPUFR-UHFFFAOYSA-L calcium;3,4,5,6-tetrahydroxy-2-oxohexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(=O)C([O-])=O.OCC(O)C(O)C(O)C(=O)C([O-])=O NNLOHLDVJGPUFR-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- -1 hyposulfites Chemical class 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VHPXSBIFWDAFMB-UHFFFAOYSA-N 2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+]C(C([O-])=O)CS1 VHPXSBIFWDAFMB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 101000716900 Arabidopsis thaliana Serine acetyltransferase 3, mitochondrial Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 102000028406 carbon-sulfur lyase Human genes 0.000 description 1
- 108010076637 carbon-sulfur lyase Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000006977 lyase reaction Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000001016 thiazine dye Substances 0.000 description 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
Definitions
- the present invention relates to a method for producing L-cysteine, and a microorganism suitable for the production of L-cysteine.
- L-cysteine and derivatives thereof are used in the fields of pharmaceuticals, cosmetics, foods and the like.
- L-cysteine is conventionally obtained by extraction from keratin-containing substances such as hair, horns, and feathers, or by conversion of precursor DL-2-aminothiazoline-4-carboxylic acid using a microbial enzyme. Large scale production of L-cysteine has been attempted using an immobilized enzyme method with a novel enzyme.
- L-cysteine has also been attempted by fermentation utilizing a microorganism.
- a method of producing L-cysteine using a microorganism has been reported, wherein said microorganism contains a DNA encoding serine acetyltransferase (SAT) with a mutation which prevents feedback inhibition by L-cysteine (WO 97/15673).
- a method of producing L-cysteine using a strain of Escherichia coli which contains a gene encoding SAT isozyme of Arabidopsis thaliana is disclosed in FEMS Microbiol. Lett., vol. 179 (1999) p 453-459. This SAT isozyme gene is resistant to feedback inhibition by L-cysteine.
- a method of producing L-cysteine using a microorganism which overexpresses a gene encoding a protein that excretes an antibiotic or a toxic substance is disclosed in JP11-56381A.
- the inventors of the present invention have disclosed a method of producing L-cysteine using a strain of Escherichia coli which contains serine acetyltransferase with reduced feedback inhibition by L-cysteine, and in which the L-cysteine-decomposing system is attenuated (JP11-155571A).
- the L-cysteine-decomposing system of the bacterium is attenuated by reduction of the intracellular activity of cysteine desulfhydrase (hereinafter, also referred to as “CD”).
- Enzymes which have been reported to have CD activity in Escherichia coli include cystathionine- ⁇ -lyase (metC gene product, hereinafter, also referred to as “CBL”) (Chandra et. al., Biochemistry, vol. 21 (1982) p 3064-3069) and tryptophanase (tnaA gene product, hereinafter, also referred to as “TNase”) (Austin Newton, et al., J. Biol. Chem. vol. 240 (1965) p 1211-1218).
- CBL cystathionine- ⁇ -lyase
- TNase tryptophanase
- An object of the present invention is to identify a gene encoding a protein having CD activity, and utilize the gene for breeding L-cysteine-producing microorganism.
- the inventors of the present invention made extensive studies and as a result, have found that the enzymes O-acetylserine sulphydrylase B (OASS-B) and MalY regulatory protein (MalY) have CD activity in Escherichia coli .
- OASS-B O-acetylserine sulphydrylase B
- MalY MalY regulatory protein
- the inventors also found that reducing CD activity by modifying these genes leads to improvement in the production of L-cysteine.
- It is a further object of the present invention to provide a method of producing L-cysteine comprising culturing the Escherichia bacterium as described above in a medium, and collecting L-cysteine from the medium.
- FIG. 1 shows the results of CD activity staining of Escherichia coli cell extracts on Native-PAGE.
- FIG. 2 shows primers used in gene disruption.
- FIG. 3 shows L-cysteine-producing ability of the control strain and each CD gene-disrupted strain; JM39 ( ⁇ ), JM39 ⁇ tnaA ( ⁇ ), JM39 ⁇ metC ( ⁇ ), JM39 ⁇ cysm (*), JM39 ⁇ malY (+), and JM39 ⁇ tnaA ⁇ metC ⁇ malY ⁇ cysM( ⁇ ).
- L-cysteine refers to a reduced-type of L-cysteine, L-cystine, or a mixture thereof.
- the Escherichia bacterium of the present invention has L-cysteine-producing ability and contains a gene encoding O-acetylserine sulphydrylase B (OASS-B) or MalY regulatory protein, wherein the gene is modified so that the cysteine desulfhydrase (CD) activity of the bacterium is reduced or eliminated.
- OASS-B O-acetylserine sulphydrylase B
- CD cysteine desulfhydrase
- the Escherichia bacterium of the present invention may have L-cysteine producing-ability and may contain both of the genes encoding OASS-B and MalY regulatory protein which are modified so that the CD activity of the bacterium is reduced or eliminated.
- one or both of the genes encoding tryptophanase (TNase) and cystathionine- ⁇ -lyase (CBL) may also be modified so that the CD activity of the bacterium is further reduced.
- L-cysteine-producing ability refers to an ability of the Escherichia bacterium of the present invention to cause accumulation of L-cysteine in a culture medium to such a degree that L-cysteine can be collected from the medium when the bacterium is cultured in the medium.
- the L-cysteine-producing ability may be imparted to a parent strain of an Escherichia bacterium by a mutation technique or a recombinant DNA technique.
- the recombinant DNA technique includes introduction of a gene encoding an L-cysteine biosynthetic enzyme.
- bacteria having native L-cysteine-producing ability may also be used.
- a bacterium imparted with an L-cysteine-producing ability by modification of a gene encoding O-acetylserine sulphydrylase B (OASS-B) or MalY regulatory protein may be used.
- the Escherichia bacteria which can be used as a parent strain include those described in Neidhardt, F. C. et al. ( Escherichia coli and Salmonella Typhimurium , American Society for Microbiology, Washington D.C., 1208, table 1), and Escherichia coli is preferably used.
- Wild-type strains of Escherichia coli include K12 strain, or mutants thereof such as Escherichia coli MG1655 strain (ATCC No. 47076) and W3110 strain (ATCC No. 27325). These bacteria strains can be obtained from the American Type Culture Collection (ATCC, Address: P.O. Box 1549, Manassas, Va. 20108, United States of America).
- the Escherichia bacteria of the present invention can be obtained by modifying a gene encoding OASS-B or MalY regulatory protein in a parent strain so that CD activity of the strain is reduced or eliminated, and then imparting an L-cysteine-producing ability to the modified strain.
- the bacteria of the present invention can also be obtained by imparting an L-cysteine-producing ability to a parent strain, and then modifying a gene encoding OASS-B or MalY regulatory protein so that CD activity of the strain is reduced or eliminated.
- One or both of the genes encoding TNase and CBL may be further modified.
- Examples of the methods of modifying a gene encoding OASS-B or MalY regulatory protein so that the CD activity of the Escherichia bacteria is reduced or eliminated include a mutation treatment method and a gene disruption method.
- Examples of the mutation treatment method include treating Escherichia bacteria with ultraviolet ray irradiation or with a mutagen used in ordinary mutation treatments, such as N-methyl-N′-nitro-N-nitrosoguanidine (NTG) or nitrous acid, and selecting mutants which contain a mutation reducing the CD activity in a gene encoding OASS-B or MalY regulatory protein.
- NTG N-methyl-N′-nitro-N-nitrosoguanidine
- nitrous acid nitrous acid
- OASS-B is encoded by the cysM gene
- MalY regulatory protein is encoded by the malY gene.
- the nucleotide sequences of these genes have been already reported (see for cysM; GenBank accession M32101 (SEQ ID NO: 33), J. Bacteriol. 172 (6), 3351-3357 (1990), and for malY; GenBank accession M60722 (SEQ ID NO: 35), J. Bacteriol. 173 (15), 4862-4876 (1991)). Accordingly, DNA fragments which can be used to disrupt the genes can be obtained by PCR using primers based on the nucleotide sequences from a chromosomal DNA of Escherichia coli .
- the cysM gene deletion mutant (deletion-type cysM gene) and the malY gene deletion mutant (deletion-type malY gene) can be obtained by PCR using the primers shown in FIG. 2 .
- DNA fragments for gene disruption are not limited to those derived from Escherichia coli , and may be DNAs derived from other organisms or synthetic DNAs as long as they can cause homologous recombination with a chromosomal DNA of a host bacterium.
- DNAs having 80% or more, preferably 90% or more, more preferably 95% or more homology to the cysM gene or malY gene of Escherichia coli may be used.
- BLAST Pro. Natl. Acad. Sci. USA, 90, and 5873 (1993)
- FASTA Methods Enzymol., 183, and 63 (1990)
- BLASTN and BLASTX programs have been developed based on this algorithm BLAST. (refer to http://www.ncbi.nlm.nih.gov).
- DNAs able to hybridize with the cysM gene or malY gene of Escherichia coli under stringent conditions may also be used. “Stringent conditions” as used herein are conditions under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed.
- examples of stringent conditions include, those under which DNAs having high homology to each other, for example, DNAs having a homology of not less than 50%, hybridize to each other, and DNAs having homology lower than 50% do not hybridize to each other, and those under which DNAs hybridize to each other at a salt concentration with washing typical of Southern hybridization, i.e., washing once or preferably 2-3 times under 1 ⁇ SSC, 0.1% SDS at 60° C., preferably 0.1 ⁇ SSC, 0.1% SDS at 60° C., more preferably 0.1 ⁇ SSC, 0.1% SDS at 68° C.
- a chromosomal cysM gene can be disrupted by transforming an Escherichia bacterium with a DNA containing a cysM gene which has part of its sequence deleted, and subsequent loss of normal OASS-B protein function (deletion-type cysM gene), and causing recombination between the deletion-type cysMgene and the chromosomal cysM gene.
- Examples of the deletion-type cysM gene used in transformation include genes having part of a sequence of the cysM gene deleted, genes having an corresponding expression regulatory region such as a promoter deleted or mutated so that of the expression of the cysM gene decreases, and genes into which a site-specific mutation is introduced so that the CD activity of a protein encoded by the cysM gene decreases.
- the gene disruption technique using homologous recombination has already been established and examples thereof include using a linear DNA or a plasmid containing a temperature-sensitive replication origin.
- plasmids containing a temperature-sensitive replication origin for Escherichia coli include pMAN031 (Yasueda, H. et al., Appl. Microbiol. Biotechnol., 36, 211 (1991)), pMAN997 (WO 99/03988), and pEL3 (K. A. Armstrong, et al., J. Mol. Biol. (1984) 175, 331-347).
- a cysM gene on a host chromosome can be replaced with the deletion-type cysM gene, for example, as follows. That is, a recombinant DNA is prepared by inserting into a vector a temperature-sensitive replication origin, a deletion-type cysM gene, and a marker gene conferring resistance to a drug such as ampicillin or chloramphenicol. Then, an Escherichia bacterium is transformed with the recombinant DNA. Furthermore, the transformant strain is cultured at a temperature at which the temperature-sensitive replication origin does not function. Then the transformant strain is cultured in a medium containing the drug to obtain the transformant strain in which the recombinant DNA is incorporated into the chromosomal DNA.
- the deletion-type cysM gene is recombined with the native cysM, and the two fusion genes of the chromosomal cysM gene and the deletion-type cysM gene are inserted into the chromosome so that the other portions of the recombinant DNA (vector segment, temperature-sensitive replication origin and drug resistance marker) are present between the two fusion genes. Therefore, the transformant strain expresses normal OASS-B because the normal cysM gene is dominant in this state.
- the deletion-type cysM gene is eliminated along with the vector segment (including the temperature-sensitive replication origin and the drug resistance marker) from the chromosomal DNA by recombination of two of the cysM genes.
- the normal cysM gene is left on the chromosomal DNA and the deletion-type cysM gene is excised from the chromosomal DNA, or to the contrary, the deletion-type cysM gene is left on the chromosomal DNA and the normal cysM gene is excised from the chromosomal DNA.
- the excised DNA may be harbored in the cell as a plasmid when the cell is cultured at a temperature which allows the temperature-sensitive replication origin to function. Subsequently, if the cell is cultured at a temperature which does not allow the temperature-sensitive replication origin to function, the cysM gene on the plasmid is eliminated with the plasmid from the cell. Then, a strain having the disrupted cysM gene left in the chromosome can be selected by PCR, Southern hybridization, or the like.
- CD activity is reduced or eliminated in the cysM gene-disrupted strain or mutant strain obtained as described above. Reduction or elimination of the CD activity in the cysM gene-disrupted strain or mutant strain can be confirmed by measuring the CD activity of a cell extract of a candidate strain by CD activity staining or quantification of hydrogen sulfide as described in the Examples, and comparing it with the CD activity of the parent or non-modified strain.
- the bacteria of the present invention may be strains in which one or both of the genes encoding tryptophanase (TNase) and cystathionine- ⁇ -lyase (CBL) are modified so that CD activity of the strain is further reduced.
- TNase tryptophanase
- CBL cystathionine- ⁇ -lyase
- the method of modifying those genes is disclosed in detail in JP-A 2003-169668 (EP1,298,200).
- L-cysteine-producing ability may be imparted to a bacterium by enhancing an activity of an L-cysteine biosynthetic enzyme.
- Enhancing an L-cysteine biosynthetic enzyme can be performed by enhancing, for example, an activity of serine acetyltransferase (SAT).
- SAT serine acetyltransferase
- Enhancing the SAT activity in cells of an Escherichia bacterium can be attained by increasing a copy number of a SAT gene.
- a recombinant DNA can be prepared by ligating a gene fragment encoding SAT to a vector that functions in Escherichia bacteria, preferably a multi-copy type vector, and transforming a host Escherichia bacterium with the vector.
- the SAT gene of the present invention may be derived from Escherichia bacteria or from any other organism.
- the cysE SAT gene has been cloned from a wild-type Escherichia coli strain and an L-cysteine-secretion mutant strain, and the nucleotide sequence has been elucidated (Denk, D. and Boeck, A., J. General Microbiol., 133, 515-525 (1987)). Therefore, a SAT gene can be obtained by PCR utilizing primers based on the nucleotide sequence (SEQ ID NO: 31) from a chromosomal DNA of Escherichia bacterium (see JP11-155571A).
- SAT gene may be able to hybridize to a DNA having the nucleotide sequence of SEQ ID NO: 31 under stringent conditions, and also may encode a protein having SAT activity, which catalyzes the activation of L-serine by acetyl-CoA.
- a chromosomal DNA can be prepared from a bacterium, which is a DNA donor, by the method of Saito and Miura (refer to H. Saito and K. Miura, Biochem. Biophys. Acta, 72, 619 1963); Text for Bioengineering Experiments, Edited by the Society for Bioscience and Bioengineering, Japan, pp. 97-98, Baifukan, 1992).
- vectors typically used for protein expression can be used.
- examples of such vectors include pUC19, pUC18, pHSG299, pHSG399, pHSG398, RSF1010, pBR322, pACYC184, pMW219, and so forth.
- a recombinant vector containing the SAT gene into Escherichia bacterium can be attained by methods typically used for transformation of Escherichia bacteria, for example, the method of D. A. Morrison (Methods in Enzymology, 68, 326 (1979)), a method of treating recipient cells with calcium chloride so as to increase the permeability for DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)), and so forth.
- Increasing a copy number of the SAT gene can also be achieved by introducing multiple copies the gene into the chromosomal DNA of an Escherichia bacterium.
- homologous recombination may be carried out by targeting a sequence which exists on a chromosomal DNA in multiple copies.
- sequences which exist on a chromosomal DNA in multi-copies repetitive DNA or an inverted repeat which exists at the ends of a transposable element can be used.
- J2-109985A it is also possible to incorporate a SAT gene into a transposon, and allow it to be transferred so that multiple copies of the gene are introduced into the chromosomal DNA.
- amplification of the SAT activity can also be attained by replacing an expression regulatory sequence such as a promoter of the SAT gene on a chromosomal DNA or on a plasmid with a stronger one (JP1-215280A).
- an expression regulatory sequence such as a promoter of the SAT gene on a chromosomal DNA or on a plasmid with a stronger one (JP1-215280A).
- JP1-215280A lac promoter, trp promoter, trc promoter, and so forth are known as strong promoters.
- substitution of an expression regulatory sequence can also be attained by, for example, gene substitution utilizing a temperature-sensitive plasmid.
- SAT gene it is also possible to substitute several nucleotides in the promoter region of the SAT gene, resulting in modification of the promoter to make it stronger as disclosed in WO00/18935. Expression of the SAT gene is enhanced by such substitution or modification of a promoter, and thereby the SAT activity is enhanced. These modifications of expression regulatory sequence may be combined with the increase of a copy number of SAT gene.
- enhancing the expression can also be enhanced by modifying an expression regulatory sequence or a gene involved in the suppression so to eliminate or reduce the suppression.
- the intracellular SAT activity of an Escherichia bacterium can also be increased by modifying an Escherichia bacterium to harbor SAT which has reduced or eliminated feedback inhibition by L-cysteine (henceforth also referred to as “mutant-type SAT”).
- mutant-type SAT include SAT having a mutation replacing the methionine at a position 256 of wild-type SAT (SEQ ID 32) with an amino acid other than lysine and leucine, or a mutation deleting a C-terminal region of SAT from the methionine at a position 256 and thereafter.
- amino acid other than lysine and leucine examples include the 17 kinds of amino acid residues which constitute ordinary proteins with the exceptions of methionine, lysine, and leucine.
- isoleucine can be mentioned.
- a site-specific mutagenesis technique can be used to introduce a desired mutation into a wild-type SAT gene.
- a mutant-type SAT gene a mutant-type cysE encoding a mutant-type SAT of Escherichia coli is known (WO97/15673 and JP11-155571A).
- Escherichia coli JM39-8 strain harboring plasmid pCEM256E, which contains a mutant-type cysE encoding a mutant-type SAT in which the methionine at a position 256 is replaced with glutamic acid E. coli JM39-8(pCEM256E), private number: AJ13391
- E. coli JM39-8(pCEM256E), private number: AJ13391 has been deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on Nov. 20, 1997 under the accession number of FERM P-16527. The original deposit was converted to an international deposit in accordance with the Budapest Treaty on Jul. 8, 2002, and given the accession number of FERM BP-8112.
- an Escherichia bacterium can be modified to contain a mutant-type SAT by introducing a mutation into a chromosomal SAT gene which prevents feedback inhibition by L-cysteine.
- the mutation can be introduced by ultraviolet irradiation or a mutagenizing agent used for usual mutagenesis treatment such as N-methyl-N′-nitro-N-nitrosoguanidine (NTG) or nitrous acid.
- SAT which is resistant to feedback inhibition by L-cysteine used in the present invention may be a SAT protein modified to be resistant to feedback inhibition, and may also be a SAT protein with a native resistance to feedback inhibition.
- SAT of Arabidopsis thaliana is known not to suffer from feedback inhibition by L-cysteine and can be suitably used in the present invention.
- pEAS-m is known (FEMS Microbiol. Lett., 179 453-459 (1999)) as a plasmid containing SAT gene derived from Arabidopsis thaliana.
- L-Cysteine can be efficiently produced by culturing the Escherichia bacterium of the present invention obtained as described above in a suitable medium to cause accumulation of L-cysteine in the culture medium, and collecting the L-cysteine from the culture medium.
- L-cysteine produced by the method of the present invention may contain cystine in addition to reduced-type cysteine
- the target substances produced by the method of the present invention include cystine and a mixture of reduced-type cysteine and cystine.
- culture media ordinary media containing a carbon source, nitrogen source, sulfur source, inorganic ions, and other organic components, if required, can be used.
- carbon sources saccharides such as glucose, fructose, sucrose, molasses, and starch hydrolysate, organic acids such as fumaric acid, citric acid and succinic acid can be used.
- nitrogen sources inorganic ammonium salts such as ammonium sulfate, ammonium chloride and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, aqueous ammonia, and so forth can be used.
- inorganic sulfur compounds such as sulfates, sulfites, sulfides, hyposulfites, and thiosulfates can be used.
- organic trace amount nutrients it is desirable to add required substances such as vitamin B1, yeast extract, and so forth in appropriate amounts.
- potassium phosphate, magnesium sulfate, iron ions, manganese ions, and so forth may be added in small amounts if required.
- the culture is preferably performed under aerobic conditions for 30 to 90 hours.
- the culture temperature is preferably controlled at 25° C. to 37° C.
- pH is preferably controlled at 5 to 8 during the culture.
- inorganic or organic, acidic or alkaline substances ammonia gas, and so forth can be used.
- Collecting L-cysteine from the culture medium can be attained by, for example, an ordinary ion exchange resin method, precipitation, and other known methods, or combinations thereof.
- JM39 ⁇ tnaA, JM39 ⁇ metC, JM39 ⁇ cysM, JM39 ⁇ malY, and JM39 ⁇ cysK as a single-CD-gene-disrupted strain
- JM39 ⁇ tnaA ⁇ metC and JM39 ⁇ cysK ⁇ cysM as a double-CD-gene-disrupted strain
- JM39 ⁇ tnaA ⁇ metC ⁇ cysM ⁇ malY as a quadruple-CD-gene-disrupted strain
- JM39 ⁇ tnaA ⁇ metC ⁇ cysK ⁇ cysM ⁇ malY as a quintuple-CD-gene-disrupted strain.
- a plasmid library containing 4,388 kinds of genes (whole ORF fragments) of E. coli was used to identify a gene encoding a protein having CD activity (4,388 kinds of plasmids were respectively dispensed into the wells of forty eight 96-well plates).
- the plasmid library covers all of the 4,388 kinds of ORF fragments of E. coli located downstream to the lac promoter in the pCA24N vector and the expression of each ORF is induced by IPTG.
- plasmid pEL3 K. A. Armstrong et al., J. Mol. Biol.
- the preparation of the cell extract from the cultured cells was performed by sonication.
- the composition of the buffer used for the sonication was 100 mM Tris-HCL (pH 8.6), 100 mM DTT (( ⁇ )-Dithiothreitol), and 10 mM PLP (pyridoxal phosphate).
- Native-PAGE gel containing no SDS was prepared for the purpose of identifying and ascertaining a protein having CD activity, confirming the construction of the CD-gene-disrupted strains, and so on, by CD activity staining described hereinbelow.
- the composition of the Native-PAGE gel for three gel sheets was 6.4 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 6.7 ml of 1 M Tris-HCl (pH 8.7), 6.8 ml of dH 2 O, 100 ⁇ l of 10% APS (Ammonium persulfate), and 10 ⁇ l of TEMED (N,N,N,N′-Tetra-methyl-ethylenediamine) for 12.5% gel, and 5.1 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 6.7 ml of 1 M Tris-HCl (pH 8.7), 8.1 ml of dH 2 O, 100 ⁇ l of 10% APS, and 10 ⁇ l of TEMED for 10% gel.
- the concentrated gel was 4.5% and its composition for three gel sheets was ⁇ 0.7 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 0.75 ml of 1 M Tris-HCl (pH 6.8), 4.52 ml of dH 2 O, 30 ⁇ l of 10% APS, and 5 ⁇ l of TEMED.
- the Native-PAGE was performed using a mini-slab electrophoretic apparatus (AEV-6500, manufactured by ATTO), and a mixture of 30 ⁇ g to 50 ⁇ g of cell extract and 2-fold Native-PAGE buffer was applied to the gel.
- the electrophoresis was performed at 200 V and 20 mA/gel for 2 hours to 4 hours.
- the composition of 1 liter of the electrophoresis buffer was 14.43 g of L-glycine and 3.0 g of Tris, and the buffer was adjusted to pH 8.6.
- a CD activity staining method was used for specifically visualizing and detecting the existence of a protein having CD activity. As described in section 1-5, after proteins in the cell extract had been separated by electrophoresis, the gel was immersed in the CD activity staining solution and left to stand at room temperature from several hours to overnight with shaking to detect the protein band having CD activity.
- the composition of 100 ml of the CD activity staining solution was 1.21 g of Tris, 0.372 g of EDTA, 0.605 g of L-cysteine, 50 mg of BiCl 3 (bismuth chloride), and 200 ⁇ l of 10 ml PLP, and the solution was adjusted to pH 8.6.
- the CD activity staining was performed based on the principle that cysteine contained in the CD activity staining solution is degraded into pyruvic acid, ammonia, and H 2 S at the site where a protein having CD activity separated with Native-PAGE exists on the gel.
- the generated H 2 S reacts with bismuth chloride (BiCl 3 ) contained in the CD activity staining solution to form bismuth sulfide (Bi 2 S 3 ), which exhibits a black color band.
- CD activity staining was performed to detect which mixed plasmid solution contained a candidate gene encoding a protein having CD activity.
- the population containing a candidate gene presumed to encode a protein having CD activity was downsized to a population of 480 kinds of plasmids, and then, further downsizing of the population to that of 96 kinds of plasmids was performed. 480 kinds of the plasmids were divided into five groups of 96 to prepare five kinds of mixed plasmid solutions. JM39 strains were transformed with the mixed plasmid solutions and about 6,000 colonies of the transformants were stocked in glycerol.
- the transformants were cultured and CD activity staining was performed to confirm if the mixed plasmid solution contains a candidate gene encoding a protein having CD activity.
- the population containing a candidate gene presumed to encode a protein having CD activity was downsized to 96 kinds of plasmids, the population was further reduced to 8 kinds of plasmids. Finally, eight proteins were each expressed from the 8 kinds of plasmids and CD activity staining was performed to confirm if they are the target protein having CD activity.
- a CD gene-disrupted strain was constructed from E. coli JM39 strain with the disruption plasmid as described in section 1-9.
- disruption plasmids were introduced into JM39 to obtain transformants.
- the limiting temperature for temperature-sensitive plasmid pEL3 is 42° C.
- the non-limiting temperature, a temperature not higher than the limiting temperature, for the plasmid is generally 37° C., which is an ordinary culture temperature for E. coli .
- the culture was performed at 30° C. in this experiment to ensure the temperature sensitivity of the plasmid. Then, after each transformant was cultured overnight at 30° C.
- the culture broth was diluted to 10 3 -fold, and 200 ⁇ l of the diluted solution was spread on the LB+Amp plate.
- Culture was performed at 42° C., which is the temperature at which the plasmid becomes unreplicable and the growth of the transformants is inhibited by Amp, and therefore no colonies form. Thereby, homologous recombination occurred between each disrupted fragment on the plasmid with suppressed replication and a homologous region on the chromosome of the JM39 strain. This allowed the whole length of the disruption plasmid to be incorporated into the chromosome.
- a standard curve was prepared by adding 10 ⁇ l aliquots of water, or 10 ⁇ l of 0.1 mM, 0.2 mM, or 2 mM of Na 2 S to the buffer and the mixture was incubated in the same way. After completion of the reaction, 100 ml of 20 mM N,N-dimethyl-p-phenyldiamine sulfate (in 7.2 N HCl) and the same amount of 30 mM FeCl 3 (in 1.2 N HCl) were added, vigorously mixed, and left to stand in the dark for 15 minutes.
- Each of the obtained transformants was inoculated in a Sakaguchi flask containing 20 ml of C1 medium with sodium thiosulfate (15 g/L thiosulfuric acid), and cultured at 37° C.
- the amount of L-cysteine in the supernatant after 24, 48, 72, and 96 hours was quantified.
- the amount of L-cysteine was measured as a total amount of reduced cysteine and cystine by the bioassay using Leuconostoc mesenteroides (Tsunoda, T. et al., Amino acids, 3, 7-13 (1961)).
- FIG. 1 shows the results. Five bands exhibiting CD activity were detected. This experiment indicates that at least five kinds of proteins having CD activity are present in E. coli . Of those, two were identified as tryptophanase (TNase) and cystathionine- ⁇ -lyase (CBL) by amino acid sequencing analysis (JP 2003-169668A). To identify the remaining three, the following experiments were performed.
- TNase tryptophanase
- CBL cystathionine- ⁇ -lyase
- the cysM gene of E. coli has been reported to encode O-acetyl L-serine sulphydrylase-B (OASS-B) (see J. Bacteriol. 172 (6), 3351-3357 (19890)).
- the cysK has been reported to encode O-acetyl L-serine sulphydrylase (OASS-A) (Mol. Microbiol. 2 (6), 777-783 (1988)).
- OASS-A O-acetyl L-serine sulphydrylase
- the malY gene encodes a MalY protein which is a regulatory factor for maltose metabolism pathway gene group and has a conformation close to that of CBL and catalyzes the C-S lyase reaction (EMBO J. 2000, March; 19(5):831-842).
- the gene disruption step was repeated to prepare multiple-disrupted strains, such as a quadruple disrupted strain JM39 ⁇ tnaA ⁇ metC ⁇ cysM ⁇ malY in which tnaA, metC, cysM, and malY were disrupted.
- gene disruption was confirmed based on the length of the DNA fragment amplified by colony PCR. Furthermore, it was confirmed by CD activity staining that the CD activity of a protein encoded by each gene was eliminated due to gene disruption.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L-cysteine is produced by culturing an Escherichia bacterium having L-cysteine producing ability and containing a gene encoding an O-acetylserine sulphydrylase B or MalY regulatory protein that is modified so that cysteine desulfhydrase activity is reduced or eliminated. The bacterium is cultured in a medium to produce and cause accumulation of L-cysteine in the medium, and collecting L-cysteine from the medium.
Description
- 1. Technical field
- The present invention relates to a method for producing L-cysteine, and a microorganism suitable for the production of L-cysteine. L-cysteine and derivatives thereof are used in the fields of pharmaceuticals, cosmetics, foods and the like.
- 2. Background art
- L-cysteine is conventionally obtained by extraction from keratin-containing substances such as hair, horns, and feathers, or by conversion of precursor DL-2-aminothiazoline-4-carboxylic acid using a microbial enzyme. Large scale production of L-cysteine has been attempted using an immobilized enzyme method with a novel enzyme.
- Furthermore, production of L-cysteine has also been attempted by fermentation utilizing a microorganism. A method of producing L-cysteine using a microorganism has been reported, wherein said microorganism contains a DNA encoding serine acetyltransferase (SAT) with a mutation which prevents feedback inhibition by L-cysteine (WO 97/15673). A method of producing L-cysteine using a strain of Escherichia coli which contains a gene encoding SAT isozyme of Arabidopsis thaliana is disclosed in FEMS Microbiol. Lett., vol. 179 (1999) p 453-459. This SAT isozyme gene is resistant to feedback inhibition by L-cysteine. Also, a method of producing L-cysteine using a microorganism which overexpresses a gene encoding a protein that excretes an antibiotic or a toxic substance is disclosed in JP11-56381A.
- Furthermore, the inventors of the present invention have disclosed a method of producing L-cysteine using a strain of Escherichia coli which contains serine acetyltransferase with reduced feedback inhibition by L-cysteine, and in which the L-cysteine-decomposing system is attenuated (JP11-155571A). The L-cysteine-decomposing system of the bacterium is attenuated by reduction of the intracellular activity of cysteine desulfhydrase (hereinafter, also referred to as “CD”).
- Enzymes which have been reported to have CD activity in Escherichia coli include cystathionine-β-lyase (metC gene product, hereinafter, also referred to as “CBL”) (Chandra et. al., Biochemistry, vol. 21 (1982) p 3064-3069) and tryptophanase (tnaA gene product, hereinafter, also referred to as “TNase”) (Austin Newton, et al., J. Biol. Chem. vol. 240 (1965) p 1211-1218). A method of producing L-cysteine using an Escherichia coli strain which has reduced activities of cystathionine-β-lyase and tryptophanase is disclosed in JP2003-169668A (EP1,298,200). However, no enzymes other than these have been previously reported to have CD activity.
- An object of the present invention is to identify a gene encoding a protein having CD activity, and utilize the gene for breeding L-cysteine-producing microorganism.
- In order to attain the above-mentioned object, the inventors of the present invention made extensive studies and as a result, have found that the enzymes O-acetylserine sulphydrylase B (OASS-B) and MalY regulatory protein (MalY) have CD activity in Escherichia coli. The inventors also found that reducing CD activity by modifying these genes leads to improvement in the production of L-cysteine.
- It is an object of the present invention to provide an Escherichia bacterium having L-cysteine-producing ability, wherein said bacterium contains a gene encoding O-acetylserine sulphydrylase B, and wherein said gene is modified so that cysteine desulfhydrase activity is reduced or eliminated.
- It is a further object of the present invention to provide an Escherichia bacterium having L-cysteine-producing ability, wherein said bacterium contains a gene encoding MalY regulatory protein, and wherein said gene is modified so that cysteine desulfhydrase activity is reduced or eliminated.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein said gene encoding O-acetylserine sulphydrylase B is disrupted.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein said gene encoding MalY regulatory protein is disrupted.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein activity of an L-cysteine biosynthetic enzyme is enhanced.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein said L-cysteine biosynthetic enzyme is serine acetyltransferase.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein said serine acetyltransferase is resistant to feedback inhibition by L-cysteine.
- It is a further object of the present invention to provide an Escherichia bacterium as described above, wherein said Escherichia bacterium is Escherichia coli.
- It is a further object of the present invention to provide a method of producing L-cysteine comprising culturing the Escherichia bacterium as described above in a medium, and collecting L-cysteine from the medium.
-
FIG. 1 shows the results of CD activity staining of Escherichia coli cell extracts on Native-PAGE. -
FIG. 2 shows primers used in gene disruption. -
FIG. 3 shows L-cysteine-producing ability of the control strain and each CD gene-disrupted strain; JM39 (), JM39ΔtnaA (▪), JM39ΔmetC (▴), JM39Δcysm (*), JM39ΔmalY (+), and JM39ΔtnaAΔmetCΔmalYΔcysM(□). - Hereinafter, the present invention will be explained in detail. In the present invention, unless otherwise described, L-cysteine refers to a reduced-type of L-cysteine, L-cystine, or a mixture thereof.
- The Escherichia bacterium of the present invention has L-cysteine-producing ability and contains a gene encoding O-acetylserine sulphydrylase B (OASS-B) or MalY regulatory protein, wherein the gene is modified so that the cysteine desulfhydrase (CD) activity of the bacterium is reduced or eliminated. The Escherichia bacterium of the present invention may have L-cysteine producing-ability and may contain both of the genes encoding OASS-B and MalY regulatory protein which are modified so that the CD activity of the bacterium is reduced or eliminated. In the Escherichia bacterium of the present invention, one or both of the genes encoding tryptophanase (TNase) and cystathionine-β-lyase (CBL) may also be modified so that the CD activity of the bacterium is further reduced.
- The term “L-cysteine-producing ability” as used herein refers to an ability of the Escherichia bacterium of the present invention to cause accumulation of L-cysteine in a culture medium to such a degree that L-cysteine can be collected from the medium when the bacterium is cultured in the medium. The L-cysteine-producing ability may be imparted to a parent strain of an Escherichia bacterium by a mutation technique or a recombinant DNA technique. The recombinant DNA technique includes introduction of a gene encoding an L-cysteine biosynthetic enzyme. Alternatively, bacteria having native L-cysteine-producing ability may also be used. Furthermore, a bacterium imparted with an L-cysteine-producing ability by modification of a gene encoding O-acetylserine sulphydrylase B (OASS-B) or MalY regulatory protein may be used.
- The Escherichia bacteria which can be used as a parent strain include those described in Neidhardt, F. C. et al. (Escherichia coli and Salmonella Typhimurium, American Society for Microbiology, Washington D.C., 1208, table 1), and Escherichia coli is preferably used. Wild-type strains of Escherichia coli include K12 strain, or mutants thereof such as Escherichia coli MG1655 strain (ATCC No. 47076) and W3110 strain (ATCC No. 27325). These bacteria strains can be obtained from the American Type Culture Collection (ATCC, Address: P.O. Box 1549, Manassas, Va. 20108, United States of America).
- The Escherichia bacteria of the present invention can be obtained by modifying a gene encoding OASS-B or MalY regulatory protein in a parent strain so that CD activity of the strain is reduced or eliminated, and then imparting an L-cysteine-producing ability to the modified strain. The bacteria of the present invention can also be obtained by imparting an L-cysteine-producing ability to a parent strain, and then modifying a gene encoding OASS-B or MalY regulatory protein so that CD activity of the strain is reduced or eliminated. One or both of the genes encoding TNase and CBL may be further modified.
- The method of obtaining the Escherichia bacteria of the present invention will be explained in detail.
- <1> Modification of a Gene Encoding OASS-B or MalY Regulatory Protein
- Examples of the methods of modifying a gene encoding OASS-B or MalY regulatory protein so that the CD activity of the Escherichia bacteria is reduced or eliminated include a mutation treatment method and a gene disruption method. Examples of the mutation treatment method include treating Escherichia bacteria with ultraviolet ray irradiation or with a mutagen used in ordinary mutation treatments, such as N-methyl-N′-nitro-N-nitrosoguanidine (NTG) or nitrous acid, and selecting mutants which contain a mutation reducing the CD activity in a gene encoding OASS-B or MalY regulatory protein. To reduce or eliminate the CD activity of OASS-B or MalY regulatory protein with high accuracy, it is preferable to disrupt a gene encoding OASS-B or MalY regulatory protein.
- In Escherichia coli, OASS-B is encoded by the cysM gene, and MalY regulatory protein is encoded by the malY gene. The nucleotide sequences of these genes have been already reported (see for cysM; GenBank accession M32101 (SEQ ID NO: 33), J. Bacteriol. 172 (6), 3351-3357 (1990), and for malY; GenBank accession M60722 (SEQ ID NO: 35), J. Bacteriol. 173 (15), 4862-4876 (1991)). Accordingly, DNA fragments which can be used to disrupt the genes can be obtained by PCR using primers based on the nucleotide sequences from a chromosomal DNA of Escherichia coli. More specifically, the cysM gene deletion mutant (deletion-type cysM gene) and the malY gene deletion mutant (deletion-type malY gene) can be obtained by PCR using the primers shown in
FIG. 2 . DNA fragments for gene disruption are not limited to those derived from Escherichia coli, and may be DNAs derived from other organisms or synthetic DNAs as long as they can cause homologous recombination with a chromosomal DNA of a host bacterium. For example, DNAs having 80% or more, preferably 90% or more, more preferably 95% or more homology to the cysM gene or malY gene of Escherichia coli may be used. Homology of the DNA sequences can be determined using the algorithm BLAST (Pro. Natl. Acad. Sci. USA, 90, and 5873 (1993)) and FASTA (Methods Enzymol., 183, and 63 (1990)) by Karlin and Altschul. The BLASTN and BLASTX programs have been developed based on this algorithm BLAST. (refer to http://www.ncbi.nlm.nih.gov). Furthermore, DNAs able to hybridize with the cysM gene or malY gene of Escherichia coli under stringent conditions may also be used. “Stringent conditions” as used herein are conditions under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed. It is difficult to clearly express this condition by using any numerical value. However, examples of stringent conditions include, those under which DNAs having high homology to each other, for example, DNAs having a homology of not less than 50%, hybridize to each other, and DNAs having homology lower than 50% do not hybridize to each other, and those under which DNAs hybridize to each other at a salt concentration with washing typical of Southern hybridization, i.e., washing once or preferably 2-3 times under 1×SSC, 0.1% SDS at 60° C., preferably 0.1×SSC, 0.1% SDS at 60° C., more preferably 0.1×SSC, 0.1% SDS at 68° C. - Hereinafter, a method of disrupting the gene encoding OASS-B will be explained. The gene encoding MalY regulatory protein can be disrupted or mutated in a similar manner.
- A chromosomal cysM gene can be disrupted by transforming an Escherichia bacterium with a DNA containing a cysM gene which has part of its sequence deleted, and subsequent loss of normal OASS-B protein function (deletion-type cysM gene), and causing recombination between the deletion-type cysMgene and the chromosomal cysM gene. Examples of the deletion-type cysM gene used in transformation include genes having part of a sequence of the cysM gene deleted, genes having an corresponding expression regulatory region such as a promoter deleted or mutated so that of the expression of the cysM gene decreases, and genes into which a site-specific mutation is introduced so that the CD activity of a protein encoded by the cysM gene decreases.
- The gene disruption technique using homologous recombination has already been established and examples thereof include using a linear DNA or a plasmid containing a temperature-sensitive replication origin. Examples of plasmids containing a temperature-sensitive replication origin for Escherichia coli include pMAN031 (Yasueda, H. et al., Appl. Microbiol. Biotechnol., 36, 211 (1991)), pMAN997 (WO 99/03988), and pEL3 (K. A. Armstrong, et al., J. Mol. Biol. (1984) 175, 331-347).
- A cysM gene on a host chromosome can be replaced with the deletion-type cysM gene, for example, as follows. That is, a recombinant DNA is prepared by inserting into a vector a temperature-sensitive replication origin, a deletion-type cysM gene, and a marker gene conferring resistance to a drug such as ampicillin or chloramphenicol. Then, an Escherichia bacterium is transformed with the recombinant DNA. Furthermore, the transformant strain is cultured at a temperature at which the temperature-sensitive replication origin does not function. Then the transformant strain is cultured in a medium containing the drug to obtain the transformant strain in which the recombinant DNA is incorporated into the chromosomal DNA.
- In the strain in which the recombinant DNA is incorporated into the chromosomal DNA as described above, the deletion-type cysM gene is recombined with the native cysM, and the two fusion genes of the chromosomal cysM gene and the deletion-type cysM gene are inserted into the chromosome so that the other portions of the recombinant DNA (vector segment, temperature-sensitive replication origin and drug resistance marker) are present between the two fusion genes. Therefore, the transformant strain expresses normal OASS-B because the normal cysM gene is dominant in this state.
- Then, in order to leave only the deletion-type cysM gene on the chromosomal DNA, one copy of the cysM gene is eliminated along with the vector segment (including the temperature-sensitive replication origin and the drug resistance marker) from the chromosomal DNA by recombination of two of the cysM genes. In this case, the normal cysM gene is left on the chromosomal DNA and the deletion-type cysM gene is excised from the chromosomal DNA, or to the contrary, the deletion-type cysM gene is left on the chromosomal DNA and the normal cysM gene is excised from the chromosomal DNA. In both cases, the excised DNA may be harbored in the cell as a plasmid when the cell is cultured at a temperature which allows the temperature-sensitive replication origin to function. Subsequently, if the cell is cultured at a temperature which does not allow the temperature-sensitive replication origin to function, the cysM gene on the plasmid is eliminated with the plasmid from the cell. Then, a strain having the disrupted cysM gene left in the chromosome can be selected by PCR, Southern hybridization, or the like.
- CD activity is reduced or eliminated in the cysM gene-disrupted strain or mutant strain obtained as described above. Reduction or elimination of the CD activity in the cysM gene-disrupted strain or mutant strain can be confirmed by measuring the CD activity of a cell extract of a candidate strain by CD activity staining or quantification of hydrogen sulfide as described in the Examples, and comparing it with the CD activity of the parent or non-modified strain.
- The bacteria of the present invention may be strains in which one or both of the genes encoding tryptophanase (TNase) and cystathionine-β-lyase (CBL) are modified so that CD activity of the strain is further reduced. The method of modifying those genes (tnaA gene or metC gene) is disclosed in detail in JP-A 2003-169668 (EP1,298,200).
- <2> Enhancing L-Cysteine Biosynthetic Enzyme Activity
- L-cysteine-producing ability may be imparted to a bacterium by enhancing an activity of an L-cysteine biosynthetic enzyme. Enhancing an L-cysteine biosynthetic enzyme can be performed by enhancing, for example, an activity of serine acetyltransferase (SAT). Enhancing the SAT activity in cells of an Escherichia bacterium can be attained by increasing a copy number of a SAT gene. For example, a recombinant DNA can be prepared by ligating a gene fragment encoding SAT to a vector that functions in Escherichia bacteria, preferably a multi-copy type vector, and transforming a host Escherichia bacterium with the vector.
- The SAT gene of the present invention may be derived from Escherichia bacteria or from any other organism. The cysE SAT gene has been cloned from a wild-type Escherichia coli strain and an L-cysteine-secretion mutant strain, and the nucleotide sequence has been elucidated (Denk, D. and Boeck, A., J. General Microbiol., 133, 515-525 (1987)). Therefore, a SAT gene can be obtained by PCR utilizing primers based on the nucleotide sequence (SEQ ID NO: 31) from a chromosomal DNA of Escherichia bacterium (see JP11-155571A). Genes encoding SAT derived from other microorganisms can also be obtained in a similar manner. The SAT gene may be able to hybridize to a DNA having the nucleotide sequence of SEQ ID NO: 31 under stringent conditions, and also may encode a protein having SAT activity, which catalyzes the activation of L-serine by acetyl-CoA.
- A chromosomal DNA can be prepared from a bacterium, which is a DNA donor, by the method of Saito and Miura (refer to H. Saito and K. Miura, Biochem. Biophys. Acta, 72, 619 1963); Text for Bioengineering Experiments, Edited by the Society for Bioscience and Bioengineering, Japan, pp. 97-98, Baifukan, 1992).
- In order to introduce the PCR-amplified DNA fragment containing a SAT gene into an Escherichia bacterium, vectors typically used for protein expression can be used. Examples of such vectors include pUC19, pUC18, pHSG299, pHSG399, pHSG398, RSF1010, pBR322, pACYC184, pMW219, and so forth.
- Introduction of a recombinant vector containing the SAT gene into Escherichia bacterium can be attained by methods typically used for transformation of Escherichia bacteria, for example, the method of D. A. Morrison (Methods in Enzymology, 68, 326 (1979)), a method of treating recipient cells with calcium chloride so as to increase the permeability for DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)), and so forth.
- Increasing a copy number of the SAT gene can also be achieved by introducing multiple copies the gene into the chromosomal DNA of an Escherichia bacterium. To introduce multiple copies of the SAT gene into the chromosomal DNA of an Escherichia bacterium, homologous recombination may be carried out by targeting a sequence which exists on a chromosomal DNA in multiple copies. As sequences which exist on a chromosomal DNA in multi-copies, repetitive DNA or an inverted repeat which exists at the ends of a transposable element can be used. Furthermore, as disclosed in J2-109985A, it is also possible to incorporate a SAT gene into a transposon, and allow it to be transferred so that multiple copies of the gene are introduced into the chromosomal DNA.
- Besides the aforementioned gene amplification technique, amplification of the SAT activity can also be attained by replacing an expression regulatory sequence such as a promoter of the SAT gene on a chromosomal DNA or on a plasmid with a stronger one (JP1-215280A). For example, lac promoter, trp promoter, trc promoter, and so forth are known as strong promoters. Substitution of an expression regulatory sequence can also be attained by, for example, gene substitution utilizing a temperature-sensitive plasmid.
- Furthermore, it is also possible to substitute several nucleotides in the promoter region of the SAT gene, resulting in modification of the promoter to make it stronger as disclosed in WO00/18935. Expression of the SAT gene is enhanced by such substitution or modification of a promoter, and thereby the SAT activity is enhanced. These modifications of expression regulatory sequence may be combined with the increase of a copy number of SAT gene.
- Furthermore, when a suppression mechanism exists for SAT gene expression, enhancing the expression can also be enhanced by modifying an expression regulatory sequence or a gene involved in the suppression so to eliminate or reduce the suppression.
- The intracellular SAT activity of an Escherichia bacterium can also be increased by modifying an Escherichia bacterium to harbor SAT which has reduced or eliminated feedback inhibition by L-cysteine (henceforth also referred to as “mutant-type SAT”). Examples of the mutant-type SAT include SAT having a mutation replacing the methionine at a position 256 of wild-type SAT (SEQ ID 32) with an amino acid other than lysine and leucine, or a mutation deleting a C-terminal region of SAT from the methionine at a position 256 and thereafter. Examples of the amino acid other than lysine and leucine include the 17 kinds of amino acid residues which constitute ordinary proteins with the exceptions of methionine, lysine, and leucine. Preferably, isoleucine can be mentioned. A site-specific mutagenesis technique can be used to introduce a desired mutation into a wild-type SAT gene. As a mutant-type SAT gene, a mutant-type cysE encoding a mutant-type SAT of Escherichia coli is known (WO97/15673 and JP11-155571A). Escherichia coli JM39-8 strain harboring plasmid pCEM256E, which contains a mutant-type cysE encoding a mutant-type SAT in which the methionine at a position 256 is replaced with glutamic acid (E. coli JM39-8(pCEM256E), private number: AJ13391), has been deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan) on Nov. 20, 1997 under the accession number of FERM P-16527. The original deposit was converted to an international deposit in accordance with the Budapest Treaty on Jul. 8, 2002, and given the accession number of FERM BP-8112.
- Furthermore, an Escherichia bacterium can be modified to contain a mutant-type SAT by introducing a mutation into a chromosomal SAT gene which prevents feedback inhibition by L-cysteine. The mutation can be introduced by ultraviolet irradiation or a mutagenizing agent used for usual mutagenesis treatment such as N-methyl-N′-nitro-N-nitrosoguanidine (NTG) or nitrous acid.
- SAT which is resistant to feedback inhibition by L-cysteine used in the present invention may be a SAT protein modified to be resistant to feedback inhibition, and may also be a SAT protein with a native resistance to feedback inhibition. SAT of Arabidopsis thaliana is known not to suffer from feedback inhibition by L-cysteine and can be suitably used in the present invention. pEAS-m is known (FEMS Microbiol. Lett., 179 453-459 (1999)) as a plasmid containing SAT gene derived from Arabidopsis thaliana.
- <3> Production of L-Cysteine
- L-Cysteine can be efficiently produced by culturing the Escherichia bacterium of the present invention obtained as described above in a suitable medium to cause accumulation of L-cysteine in the culture medium, and collecting the L-cysteine from the culture medium. Although L-cysteine produced by the method of the present invention may contain cystine in addition to reduced-type cysteine, the target substances produced by the method of the present invention include cystine and a mixture of reduced-type cysteine and cystine.
- As culture media, ordinary media containing a carbon source, nitrogen source, sulfur source, inorganic ions, and other organic components, if required, can be used. As carbon sources, saccharides such as glucose, fructose, sucrose, molasses, and starch hydrolysate, organic acids such as fumaric acid, citric acid and succinic acid can be used. As nitrogen sources, inorganic ammonium salts such as ammonium sulfate, ammonium chloride and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, aqueous ammonia, and so forth can be used. As sulfur sources, inorganic sulfur compounds, such as sulfates, sulfites, sulfides, hyposulfites, and thiosulfates can be used. As organic trace amount nutrients, it is desirable to add required substances such as vitamin B1, yeast extract, and so forth in appropriate amounts. In addition to these components, potassium phosphate, magnesium sulfate, iron ions, manganese ions, and so forth may be added in small amounts if required.
- The culture is preferably performed under aerobic conditions for 30 to 90 hours. The culture temperature is preferably controlled at 25° C. to 37° C., and pH is preferably controlled at 5 to 8 during the culture. To adjust the pH, inorganic or organic, acidic or alkaline substances, ammonia gas, and so forth can be used. Collecting L-cysteine from the culture medium can be attained by, for example, an ordinary ion exchange resin method, precipitation, and other known methods, or combinations thereof.
- Hereinafter, the present invention will be explained in detail by the following non-limiting examples.
- Strains
- cysE-deficient Escherichia coli JM39 (F+ cysE51 tfr-8) (Denk, D. and Bock, A., J. Gene. Microbiol., 133, 515-525 (1987)) was used to identify a gene encoding a protein having CD activity.
- To evaluate L-cysteine productivity of the CD-gene-disrupted strains, the following strains were used: JM39ΔtnaA, JM39ΔmetC, JM39ΔcysM, JM39ΔmalY, and JM39ΔcysK as a single-CD-gene-disrupted strain; JM39ΔtnaAΔmetC and JM39ΔcysKΔcysM as a double-CD-gene-disrupted strain; JM39ΔtnaAΔmetCΔcysMΔmalY as a quadruple-CD-gene-disrupted strain; and JM39ΔtnaAΔmetCΔcysKΔcysMΔmalY as a quintuple-CD-gene-disrupted strain. In the production of L-cysteine, a total of six strains, including JM39, single-CD-gene-disrupted strains of JM39ΔtnaA, JM39ΔmetC, JM39ΔcysM, and JM39ΔmalY, and quadruple-CD-gene-disrupted strain JM39ΔtnaAΔmetCΔcysMΔmalY, all of which harbors pEAS-m, a plasmid containing SAT gene of Arabidopsis thaliana (FEMS Microbiol. Lett., 179 (1999) 453-459) were used.
- Plasmids
- A plasmid library containing 4,388 kinds of genes (whole ORF fragments) of E. coli was used to identify a gene encoding a protein having CD activity (4,388 kinds of plasmids were respectively dispensed into the wells of forty eight 96-well plates). The plasmid library covers all of the 4,388 kinds of ORF fragments of E. coli located downstream to the lac promoter in the pCA24N vector and the expression of each ORF is induced by IPTG. For gene disruption, plasmid pEL3 (K. A. Armstrong et al., J. Mol. Biol. (1984) 175, 331-347) was used to construct pEL3gdtnaA, pEL3gdmetC, pEL3gdcysM, pEL3gdcysK, and pEL3gdmalY. The construction of the plasmids will be described below.
- Culture Media
- For transformation and culture of E. coli, LB medium was used as a complete medium, and M9 medium (6 g/L Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, 0.25 g/L MgSO4.7H2, 0.015 mg/L CaCl2.4H2O, 4 g/L glucose, and 0.001 g/L thiamine hydrochloride) was used as a minimum medium. Ampicillin (Amp) was added if necessary. In some experiments, LB liquid medium to which 10 to 30 mM cysteine was added was used. Unless otherwise described, the culture was performed at 37° C. For the culture of cysteine production (30 g/L glucose, 10 g/L NH4Cl, 2 g/L KH2PO4, 1 g/L MgSO4.7H2O, 10 mg/L FeSO4.7H2O, 10 mg/L MnCl2.4H2O, and 20 g/L CaCO3) sodium thiosulfate was added to the culture. The same medium was used to determine the quantity of cysteine.
- Preparation of Cell Extract
- The preparation of the cell extract from the cultured cells was performed by sonication. The composition of the buffer used for the sonication was 100 mM Tris-HCL (pH 8.6), 100 mM DTT ((±)-Dithiothreitol), and 10 mM PLP (pyridoxal phosphate).
- Composition of Native-PAGE gel and procedure of Native-PAGE (Polyacrylamide gel electrophoresis under undenatured conditions)
- Since it was necessary to separate proteins in the cell extract under an undenatured state, Native-PAGE gel containing no SDS was prepared for the purpose of identifying and ascertaining a protein having CD activity, confirming the construction of the CD-gene-disrupted strains, and so on, by CD activity staining described hereinbelow. The composition of the Native-PAGE gel for three gel sheets was 6.4 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 6.7 ml of 1 M Tris-HCl (pH 8.7), 6.8 ml of dH2O, 100 μl of 10% APS (Ammonium persulfate), and 10 μl of TEMED (N,N,N,N′-Tetra-methyl-ethylenediamine) for 12.5% gel, and 5.1 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 6.7 ml of 1 M Tris-HCl (pH 8.7), 8.1 ml of dH2O, 100 μl of 10% APS, and 10 μl of TEMED for 10% gel. The concentrated gel was 4.5% and its composition for three gel sheets was {0.7 ml of Acrylamide/Bisacrylamide/amide (37:5:1), 0.75 ml of 1 M Tris-HCl (pH 6.8), 4.52 ml of dH2O, 30 μl of 10% APS, and 5 μl of TEMED. The Native-PAGE was performed using a mini-slab electrophoretic apparatus (AEV-6500, manufactured by ATTO), and a mixture of 30 μg to 50 μg of cell extract and 2-fold Native-PAGE buffer was applied to the gel. The electrophoresis was performed at 200 V and 20 mA/gel for 2 hours to 4 hours. The composition of 1 liter of the electrophoresis buffer was 14.43 g of L-glycine and 3.0 g of Tris, and the buffer was adjusted to pH 8.6.
- CD Activity Staining
- A CD activity staining method was used for specifically visualizing and detecting the existence of a protein having CD activity. As described in section 1-5, after proteins in the cell extract had been separated by electrophoresis, the gel was immersed in the CD activity staining solution and left to stand at room temperature from several hours to overnight with shaking to detect the protein band having CD activity. The composition of 100 ml of the CD activity staining solution was 1.21 g of Tris, 0.372 g of EDTA, 0.605 g of L-cysteine, 50 mg of BiCl3 (bismuth chloride), and 200 μl of 10 ml PLP, and the solution was adjusted to pH 8.6. The CD activity staining was performed based on the principle that cysteine contained in the CD activity staining solution is degraded into pyruvic acid, ammonia, and H2S at the site where a protein having CD activity separated with Native-PAGE exists on the gel. The generated H2S reacts with bismuth chloride (BiCl3) contained in the CD activity staining solution to form bismuth sulfide (Bi2S3), which exhibits a black color band.
- Identification of a Gene Encoding a Protein Having CD Activity using a Plasmid Library Containing E. Coli Whole Genes
- The forty-eight 96-well plates on which respective plasmids were dispensed were grouped into 5 plates such as 1 to 5, 6 to 10 . . . , and nine kinds of mixed plasmid solutions obtained from five plates (each containing 480 kinds of plasmids) were prepared. The mixed plasmid solutions were used to transform JM39 strains and about 10,000 colonies of transformants were stocked in glycerol. The nine kinds of glycerol-stock solutions were inoculated into LB medium containing chloramphenicol (Cm) and 0.01 mM IPTG and cultured. Then, cell extract was prepared and subjected to Native-PAGE. CD activity staining was performed to detect which mixed plasmid solution contained a candidate gene encoding a protein having CD activity. The population containing a candidate gene presumed to encode a protein having CD activity was downsized to a population of 480 kinds of plasmids, and then, further downsizing of the population to that of 96 kinds of plasmids was performed. 480 kinds of the plasmids were divided into five groups of 96 to prepare five kinds of mixed plasmid solutions. JM39 strains were transformed with the mixed plasmid solutions and about 6,000 colonies of the transformants were stocked in glycerol. Thereafter, the transformants were cultured and CD activity staining was performed to confirm if the mixed plasmid solution contains a candidate gene encoding a protein having CD activity. After the population containing a candidate gene presumed to encode a protein having CD activity was downsized to 96 kinds of plasmids, the population was further reduced to 8 kinds of plasmids. Finally, eight proteins were each expressed from the 8 kinds of plasmids and CD activity staining was performed to confirm if they are the target protein having CD activity.
- Construction of Plasmids for CD Gene Disruption
- To disrupt each CD gene, five kinds of plasmids for gene disruption, i.e., pEL3gdtnaA, pEL3gdmetC, pEL3gdcysM, pEL3gdcysK, and pEL3dgmalY were constructed using plasmid pEL3 having a temperature-sensitive replication origin. The preparation methods for these plasmids are described below. That is, using the genome of E. coli JM39 as a template, two kinds of 300 to 700 bp DNA fragments each covering a part of the respective CD gene was amplified by PCR. The DNA fragments were designated homologous region DNA fragments-A and -B, respectively. The primers used are described in
FIG. 2 . For the amplification of the homologous region DNA fragment-A, CD gene disruption primers-1 and -2 were used, and for the amplification of the homologous region DNA fragment-B, CD gene disruption primers-3 and -4 were used. These primers had a restriction enzyme recognition site at the 5′-side so that the amplified homologous region DNA fragments contain restriction enzyme recognition sites at both ends. After treatment with appropriate restriction enzymes of both fragments A and B (KpnI, HindIII, or EcoRI), both the enzyme-treated fragments were ligated to each other to form a template for preparing CD gene disruption fragments. The CD gene disruption fragments were prepared in large amounts by PCR using the CD gene disruption primers-1 and -4. The disruption fragments and pEL3 were treated with the restriction enzyme BamHI and ligated to each other to construct the CD gene disruption plasmids. The construction was confirmed by DNA sequencing. - Disruption of CD Gene
- A CD gene-disrupted strain was constructed from E. coli JM39 strain with the disruption plasmid as described in section 1-9. First, disruption plasmids were introduced into JM39 to obtain transformants. The limiting temperature for temperature-sensitive plasmid pEL3 is 42° C. Alternatively, the non-limiting temperature, a temperature not higher than the limiting temperature, for the plasmid is generally 37° C., which is an ordinary culture temperature for E. coli. However, the culture was performed at 30° C. in this experiment to ensure the temperature sensitivity of the plasmid. Then, after each transformant was cultured overnight at 30° C. in an LB+Amp medium, the culture broth was diluted to 103-fold, and 200 μl of the diluted solution was spread on the LB+Amp plate. Culture was performed at 42° C., which is the temperature at which the plasmid becomes unreplicable and the growth of the transformants is inhibited by Amp, and therefore no colonies form. Thereby, homologous recombination occurred between each disrupted fragment on the plasmid with suppressed replication and a homologous region on the chromosome of the JM39 strain. This allowed the whole length of the disruption plasmid to be incorporated into the chromosome. Then, the recombinant strain was selected which was able to form an Amp resistant colony by incorporation of the disruption plasmid. The incorporation of the disruption plasmid into the chromosome was confirmed by PCR using FW and RV of each CD gene disruption primer as described in
FIG. 2 . The colony having a confirmed disruption plasmid incorporated into the chromosome was cultured in an LB liquid medium to cause further homologous recombination. This was done so that the disrupted fragment remains on the chromosome and the fragment containing a plasmid sequence and a chromosomal gene is removed. The transformants were subcultured several times in an LB liquid medium. Then, the culture broth was spread on an LB agar medium after dilution to a concentration that would cause 200 to 300 colonies to form on the LB agar medium. The colonies were replicated on an LB plate and an LB+Amp agar plate to select for Amp-sensitive colonies. By performing colony PCR using FW and RV primers, CD-gene-disrupted strains having only the disrupted fragment on the chromosome were selected. - The CD-gene-disrupted strains were subjected to CD activity staining and disappearance of the CD activity due to gene disruption was confirmed. A multiple CD-gene-disrupted strain was constructed by repeating the operation of disrupting the target CD genes.
- Measurement of Total CD Activity (sulfide/H2S Quantification)
- The total CD activity in the cell extract was measured by determining the amount of hydrogen sulfide (H2S) generated by degradation of cysteine by CD. A strain was cultured in 5 ml of LB medium and 5 ml of LB+10 mM cysteine medium at 37° C. overnight, and then the cell extract was prepared as in the section 2-2-4. The composition of the buffer used for measuring the CD activity was 100 mM Tris-HCl (pH 8.6), 100 μM DTT, 10 mM PLP, 2 μM L-cysteine. 10 ml of the cell extract was added to 1 ml of the buffer and the reaction was carried out at 30° C. for 10 minutes. A standard curve was prepared by adding 10 μl aliquots of water, or 10 μl of 0.1 mM, 0.2 mM, or 2 mM of Na2S to the buffer and the mixture was incubated in the same way. After completion of the reaction, 100 ml of 20 mM N,N-dimethyl-p-phenyldiamine sulfate (in 7.2 N HCl) and the same amount of 30 mM FeCl3 (in 1.2 N HCl) were added, vigorously mixed, and left to stand in the dark for 15 minutes. Iron chloride acts as an oxidizing agent under acidic conditions adjusted by hydrochloric acid, and the N,N-dimethyl-p-phenyldiamine sulfate reacts with a sulfide in the sample to form a thiazine dye. As a result, Methylene Blue exhibits a greenish blue or blue color. The mixture was left to stand for 15 minutes, then, OD650 of the reaction mixture was measured and the activity was calculated by defining an amount of enzyme giving 1 μmol H2S as 1U.
- Cysteine Production Culture
- Each of the obtained transformants was inoculated in a Sakaguchi flask containing 20 ml of C1 medium with sodium thiosulfate (15 g/L thiosulfuric acid), and cultured at 37° C. The amount of L-cysteine in the supernatant after 24, 48, 72, and 96 hours was quantified. The amount of L-cysteine was measured as a total amount of reduced cysteine and cystine by the bioassay using Leuconostoc mesenteroides (Tsunoda, T. et al., Amino acids, 3, 7-13 (1961)).
- 2. Results
- 2-1. Confirmation of Existence of a Protein having CD Activity in E. coli
- To confirm the existence of a protein having CD activity in E. coli, a cell extract of JM39 strain was prepared and subjected to Native-PAGE, and electrophoresis was performed for about 2 hours to separate proteins, which was then subjected to activity staining.
FIG. 1 shows the results. Five bands exhibiting CD activity were detected. This experiment indicates that at least five kinds of proteins having CD activity are present in E. coli. Of those, two were identified as tryptophanase (TNase) and cystathionine-β-lyase (CBL) by amino acid sequencing analysis (JP 2003-169668A). To identify the remaining three, the following experiments were performed. - 2-3. Identification of the Unidentified CD Proteins using E. coli Total Gene Plasmid Library
- The genome of E. coli is presumed to have a total of 4,388 genes (ORF). Using the E. coli whole ORF library in which all ORFs were inserted into each plasmid, the operation for identification of a protein having a CD activity was repeated by the procedure described in the section 1-7. By detecting the band of the unidentified CD protein by CD activity staining, the population of plasmids containing a gene encoding an unidentified CD protein was reduced from 4,388 kinds to 480 kinds, 96 kinds, and 8 kinds, sequentially. Finally, the selected 8 kinds of plasmids were analyzed and the proteins encoded by the cysM gene, cysK gene, and malY gene were found to be the unidentified CD proteins. The cysM gene of E. coli has been reported to encode O-acetyl L-serine sulphydrylase-B (OASS-B) (see J. Bacteriol. 172 (6), 3351-3357 (19890)). The cysK has been reported to encode O-acetyl L-serine sulphydrylase (OASS-A) (Mol. Microbiol. 2 (6), 777-783 (1988)). Furthermore, it has been reported that the malY gene encodes a MalY protein which is a regulatory factor for maltose metabolism pathway gene group and has a conformation close to that of CBL and catalyzes the C-S lyase reaction (EMBO J. 2000, March; 19(5):831-842).
- 2-4. Confirmation of CD Activity
- The OASS-B, OASS-A, and MalY identified in section 2-3 were confirmed to have the CD activity by overexpressing the genes in the JM39 strain. That is, when the respective genes were overexpressed and protein bands of cell extract were analyzed by CD activity staining, the stained band was denser than the band of the control JM strain, indicating that each gene encodes a protein having CD activity.
- 2-5. Construction of CD-Gene-Disrupted Strain
- Then, each CD-gene-disrupted strain was constructed. Methods of preparing JM39ΔtnaA and JM39ΔmetC strains are disclosed in JP 2003-169668A. First, disruption plasmids pEL3gdtnaA, pEL3gdmetC, pEL3gdcysM, pEL3gdcysK, and pEL3gdmalY for disrupting tnaA, metC, cysM, cysK, and malY, respectively, were constructed and introduced into the JM39 strain to construct single-disrupted strains by homologous recombination. Furthermore, the gene disruption step was repeated to prepare multiple-disrupted strains, such as a quadruple disrupted strain JM39ΔtnaAΔmetCΔcysMΔmalY in which tnaA, metC, cysM, and malY were disrupted. After the operation of gene disruption, gene disruption was confirmed based on the length of the DNA fragment amplified by colony PCR. Furthermore, it was confirmed by CD activity staining that the CD activity of a protein encoded by each gene was eliminated due to gene disruption.
- 2-6. Measurement of Total CD Activity
- According to the method in the section 1-11, the total CD activities of all the CD-gene-disrupted strains used in this experiment were measured. The results are shown in Table 1. As a result, comparison of the total CD activity of each strain cultured in LB medium with that of the parent strain JM39 indicated a decrease in the CD activity for all the disrupted strains. Comparison of the activity of the multiple-disrupted strain with the activity of JM39 indicated a considerable decrease in the CD activity except for JM39ΔcysKΔcysM. The decrease in the CD activity in multi-disrupted strains was significant as compared with the decrease in the activity in each single-disrupted strain. The activity of JM39ΔcysKΔcysM decreased as compared with the activities of single-disrupted strains. Then, the total CD activity of the CD-gene-disrupted strain cultured in a medium to which cysteine was added was analyzed. In the strains other than JM39ΔtnaA, the CD activity of the strain cultured in a cysteine-containing medium increased considerably as compared with the CD activity of the same strain cultured in an LB medium.
-
TABLE 1 total CD activity (mU/mg) medium LB + 10 mM Strain LB L-cysteine JM39 20.6 ± 0 27.6 ± 0 JM39ΔtnaA 15.7 ± 0 14.1 ± 0 JM39ΔmetC 15.0 ± 0 27.6 ± 0.46 JM39ΔcysK 18.2 ± 0.52 29.9 ± 0 JM39ΔcysM 17.9 ± 0.46 27.8 ± 0 JM39ΔmalY 15.3 ± 0 27.1 ± 0.46 JM39ΔtnaADmetC 9.6 ± 0 16.2 ± 0 JM39ΔcysKΔcysM 17.2 ± 0.58 27.0 ± 0 JM39ΔtnaADmetCΔcysMΔmalY 9.1 ± 0.46 19.6 ± 0 JM39ΔtnaADmetCΔcysKΔcysMΔmalY 8.7 ± 0.46 11.5 ± 0 - 2-7. Cysteine Production using CD-Gene-Disrupted Strains
- pEAS-m, a plasmid containing SAT-m gene of A. thaliana, was introduced into a total of six strains, i.e., a control JM39 strain, four single-CD-gene-disrupted strains of JM39ΔtnaA, JM39ΔmetC, JM39ΔcysM, and JM39ΔmalY, and a quadruple-CD-gene-disrupted strain of JM39ΔtnaAΔmetCΔmalYΔcysM, and the transformants were used for the production of cysteine. Cysteine production culture was performed according to the method in the section 1-12 and the amount of produced cysteine was quantified. Time courses of the amounts of produced cysteine of the control strain and each of the CD-gene-disrupted strain per growth (growth: value of OD562) are shown in Table 2 and
FIG. 3 . The growth decreased slightly in the case of JM39ΔtnaA but the growth of other disrupted strains was substantially the same as that of the control strain JM39. -
TABLE 2 L-Cys (mg/L) hr Strain 24 48 72 96 JM39 416 ± 96 720 ± 161 587 ± 164 415 ± 111 JM39ΔtnaA 1206 ± 26 1195 ± 95 1287 ± 74 1077 ± 124 JM39ΔmetC 1408 ± 98 930 ± 47 1243 ± 101 853 ± 13 JM39ΔmalY 1291 ± 95 1213 ± 93 1359 ± 87 1256 ± 75 JM39ΔcysM 1369 ± 67 1123 ± 148 1100 ± 66 840 ± 56 JM39ΔtnaAΔmetCΔmalYΔcysM 1291 ± 21 1117 ± 21 1080 ± 13 847 ± 69 - The L-cysteine production of the respective gene-disrupted strains exceeded the value of the control strain JM39. Therefore, the disruption of the CD genes to inhibit the CD activity is effective for increasing the production of cysteine. When cysK gene-disrupted strains were used, almost no cysteine could be obtained when a cysteine production C1 medium containing sodium thiosulfate was used.
- By using the bacteria of the present invention, L-cysteine can be produced efficiently. L-cysteine and its derivatives are useful in the fields of medicine, cosmetics, foods, and the like.
- While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention. Each of the aforementioned documents, including the foreign priority documents, Japanese Patent No. 2004-060483 filed on Mar. 4, 2004, is incorporated by reference herein in its entirety.
Claims (12)
1. An Escherichia bacterium having L-cysteine-producing ability, wherein said bacterium contains a gene encoding O-acetylserine sulphydrylase B, and wherein said gene is modified so that cysteine desulfhydrase activity is reduced or eliminated.
2. An Escherichia bacterium having L-cysteine producing ability, wherein said bacterium contains a gene encoding MalY regulatory protein, and wherein said gene is modified so that cysteine desulfhydrase activity is reduced or eliminated.
3. The Escherichia bacterium according to claim 1 , wherein said gene encoding O-acetylserine sulphydrylase B is disrupted.
4. The Escherichia bacterium according to claim 2 , wherein said gene encoding MalY regulatory protein is disrupted.
5. The Escherichia bacterium according to claim 1 , wherein activity of an L-cysteine biosynthetic enzyme is enhanced.
6. The Escherichia bacterium according to claim 5 , wherein said L-cysteine biosynthetic enzyme is serine acetyltransferase.
7. The Escherichia bacterium according to claim 6 , wherein said serine acetyltransferase is resistant to feedback inhibition by L-cysteine.
8. The Escherichia bacterium according to claim 1 , wherein said Escherichia bacterium is Escherichia coli.
9. A method of producing L-cysteine comprising culturing the Escherichia bacterium according to claim 1 in a medium, and collecting L-cysteine from the medium.
10. The Escherichia bacterium according to claim 2 , wherein activity of an L-cysteine biosynthetic enzyme is enhanced.
11. The Escherichia bacterium according to claim 2 , wherein said Escherichia bacterium is Escherichia coli.
12. A method of producing L-cysteine comprising culturing the Escherichia bacterium according to claim 2 in a medium, and collecting L-cysteine from the medium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/635,404 US8114649B2 (en) | 2004-03-04 | 2009-12-10 | L-cysteine producing microorganism and a method for producing L-cysteine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-060483 | 2004-03-04 | ||
JP2004060483A JP4479283B2 (en) | 2004-03-04 | 2004-03-04 | L-cysteine producing bacterium and method for producing L-cysteine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/635,404 Division US8114649B2 (en) | 2004-03-04 | 2009-12-10 | L-cysteine producing microorganism and a method for producing L-cysteine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080076163A1 true US20080076163A1 (en) | 2008-03-27 |
Family
ID=34747666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/070,084 Abandoned US20080076163A1 (en) | 2004-03-04 | 2005-03-03 | L-cysteine-producing microorganism and a method for producing L-cysteine |
US12/635,404 Active 2025-07-21 US8114649B2 (en) | 2004-03-04 | 2009-12-10 | L-cysteine producing microorganism and a method for producing L-cysteine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/635,404 Active 2025-07-21 US8114649B2 (en) | 2004-03-04 | 2009-12-10 | L-cysteine producing microorganism and a method for producing L-cysteine |
Country Status (4)
Country | Link |
---|---|
US (2) | US20080076163A1 (en) |
EP (2) | EP1849874B1 (en) |
JP (1) | JP4479283B2 (en) |
DE (2) | DE602005021158D1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090226983A1 (en) * | 2008-03-06 | 2009-09-10 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US20090226984A1 (en) * | 2008-03-06 | 2009-09-10 | Gen Nonaka | L-cysteine producing bacterium and a method for producing l-cysteine |
US20100209977A1 (en) * | 2009-02-16 | 2010-08-19 | Kazuhiro Takumi | L-amino acid-producing bacterium and a method for producing an l-amino acid |
US20100216196A1 (en) * | 2009-02-25 | 2010-08-26 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US20100233765A1 (en) * | 2009-03-12 | 2010-09-16 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US20110033902A1 (en) * | 2008-02-21 | 2011-02-10 | Gen Nonaka | l-cysteine-producing bacterium and a method for producing l-cysteine |
US8647847B2 (en) | 2009-11-30 | 2014-02-11 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium and a method for producing L-cysteine |
US8962284B2 (en) | 2010-09-14 | 2015-02-24 | Ajinomoto Co., Inc. | Sulfur-containing amino acid-producing bacterium and method for producing sulfur-containing amino acid |
US9234223B2 (en) | 2011-04-01 | 2016-01-12 | Ajinomoto Co., Inc. | Method for producing L-cysteine |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007007333A1 (en) | 2007-02-14 | 2008-08-21 | Wacker Chemie Ag | Process for the purification of L-cysteine |
JP2014087259A (en) | 2011-02-22 | 2014-05-15 | Ajinomoto Co Inc | L-cysteine-producing bacterium, and production method of l-cysteine |
JP6020443B2 (en) | 2011-04-01 | 2016-11-02 | 味の素株式会社 | Method for producing L-cysteine |
JP2014131487A (en) | 2011-04-18 | 2014-07-17 | Ajinomoto Co Inc | Method for producing l-cysteine |
DE102011075656A1 (en) | 2011-05-11 | 2012-03-29 | Wacker Chemie Ag | Producing L-cystine useful as food additive, preferably in baking industry, as ingredient in cosmetics and as starting material for producing active pharmaceutical ingredient, comprises fermenting microorganism strain in fermentation medium |
DE102011078481A1 (en) | 2011-06-30 | 2013-01-03 | Wacker Chemie Ag | Process for the fermentative production of natural L-cysteine |
DE102012208359A1 (en) | 2012-05-18 | 2013-11-21 | Wacker Chemie Ag | Process for the fermentative production of L-cysteine and derivatives of this amino acid |
DE102012216527A1 (en) | 2012-09-17 | 2014-03-20 | Wacker Chemie Ag | Process for the fermentative production of L-cysteine and derivatives of this amino acid |
US9611461B2 (en) | 2013-03-19 | 2017-04-04 | National University Corporation NARA Institute of Science and Technology | Enterobacteriaceae bacteria exhibiting increased L-cysteine producing ability |
KR101607741B1 (en) | 2013-03-20 | 2016-03-31 | 씨제이제일제당 (주) | Microorganisms having putrescine productivity and process for producing putrescine using the same |
JP2016165225A (en) | 2013-07-09 | 2016-09-15 | 味の素株式会社 | Method for producing useful substance |
JP6459962B2 (en) | 2013-10-21 | 2019-01-30 | 味の素株式会社 | Method for producing L-amino acid |
JP7066977B2 (en) | 2017-04-03 | 2022-05-16 | 味の素株式会社 | Manufacturing method of L-amino acid |
KR20190092951A (en) | 2018-01-31 | 2019-08-08 | 씨제이제일제당 (주) | Method for Preparing Natural L-cysteine Crystals by Continuous Chromatography |
KR20190092950A (en) | 2018-01-31 | 2019-08-08 | 씨제이제일제당 (주) | Method for Preparing Natural L-cysteine Hydrochloride Hydrate Crystals by Continuous Chromatography |
WO2020071538A1 (en) | 2018-10-05 | 2020-04-09 | Ajinomoto Co., Inc. | Method for producing target substance by bacterial fermentation |
BR112021014194A2 (en) | 2019-02-22 | 2021-12-28 | Ajinomoto Kk | Method for producing an l-amino acid |
WO2020204179A1 (en) | 2019-04-05 | 2020-10-08 | Ajinomoto Co., Inc. | Method of producing l-amino acids |
CN110317766B (en) * | 2019-05-23 | 2020-08-28 | 浙江工业大学 | Genetically engineered bacterium capable of highly producing L-cysteine, construction method and application |
WO2021060438A1 (en) | 2019-09-25 | 2021-04-01 | Ajinomoto Co., Inc. | Method for producing l-amino acids by bacterial fermentation |
CN116018400A (en) | 2020-06-26 | 2023-04-25 | 瓦克化学股份公司 | Improved cysteine producing strains |
WO2023165684A1 (en) | 2022-03-01 | 2023-09-07 | Wacker Chemie Ag | Improved cysteine-producing strains |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050112731A1 (en) * | 2003-07-16 | 2005-05-26 | Tatsuki Kashiwagi | Mutant serine acetyltransferase |
US7052896B2 (en) * | 2000-08-08 | 2006-05-30 | Matthew Glenn | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539952A1 (en) * | 1995-10-26 | 1997-04-30 | Consortium Elektrochem Ind | Process for the preparation of O-acetylserine, L-cysteine and L-cysteine-related products |
DE19726083A1 (en) | 1997-06-19 | 1998-12-24 | Consortium Elektrochem Ind | Microorganisms and processes for the fermentative production of L-cysteine, L-cystine, N-acetyl-serine or thiazolidine derivatives |
JP4151094B2 (en) * | 1997-11-25 | 2008-09-17 | 味の素株式会社 | Method for producing L-cysteine |
EP1645623B1 (en) * | 2001-09-28 | 2009-01-07 | Ajinomoto Co., Inc. | L-cysteine producing bacterium and method for producing L-cysteine |
JP4186564B2 (en) | 2001-09-28 | 2008-11-26 | 味の素株式会社 | L-cysteine producing bacterium and method for producing L-cysteine |
JP2006517796A (en) * | 2003-02-18 | 2006-08-03 | メタボリック エクスプローラー | Method for producing an evolved microorganism capable of generating or modifying a metabolic pathway |
-
2004
- 2004-03-04 JP JP2004060483A patent/JP4479283B2/en not_active Expired - Fee Related
-
2005
- 2005-03-03 US US11/070,084 patent/US20080076163A1/en not_active Abandoned
- 2005-03-04 DE DE602005021158T patent/DE602005021158D1/en active Active
- 2005-03-04 EP EP07003442A patent/EP1849874B1/en not_active Expired - Fee Related
- 2005-03-04 EP EP05004829A patent/EP1571223B1/en not_active Expired - Fee Related
- 2005-03-04 DE DE602005018981T patent/DE602005018981D1/en active Active
-
2009
- 2009-12-10 US US12/635,404 patent/US8114649B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7052896B2 (en) * | 2000-08-08 | 2006-05-30 | Matthew Glenn | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
US20050112731A1 (en) * | 2003-07-16 | 2005-05-26 | Tatsuki Kashiwagi | Mutant serine acetyltransferase |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110033902A1 (en) * | 2008-02-21 | 2011-02-10 | Gen Nonaka | l-cysteine-producing bacterium and a method for producing l-cysteine |
US8278075B2 (en) | 2008-02-21 | 2012-10-02 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium and a method for producing L-cysteine |
US8383372B2 (en) | 2008-03-06 | 2013-02-26 | Ajinomoto Co., Inc. | L-cysteine producing bacterium and a method for producing L-cysteine |
US8008048B2 (en) | 2008-03-06 | 2011-08-30 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium and a method for producing L-cysteine |
US20090226984A1 (en) * | 2008-03-06 | 2009-09-10 | Gen Nonaka | L-cysteine producing bacterium and a method for producing l-cysteine |
US20090226983A1 (en) * | 2008-03-06 | 2009-09-10 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US20100209977A1 (en) * | 2009-02-16 | 2010-08-19 | Kazuhiro Takumi | L-amino acid-producing bacterium and a method for producing an l-amino acid |
US9458206B2 (en) | 2009-02-16 | 2016-10-04 | Ajinomoto Co., Inc. | L-amino acid-producing bacterium and a method for producing an L-amino acid |
US20100216196A1 (en) * | 2009-02-25 | 2010-08-26 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US8293506B2 (en) | 2009-02-25 | 2012-10-23 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium and a method for producing L-cysteine |
US20100233765A1 (en) * | 2009-03-12 | 2010-09-16 | Gen Nonaka | L-cysteine-producing bacterium and a method for producing l-cysteine |
US8647847B2 (en) | 2009-11-30 | 2014-02-11 | Ajinomoto Co., Inc. | L-cysteine-producing bacterium and a method for producing L-cysteine |
US8962284B2 (en) | 2010-09-14 | 2015-02-24 | Ajinomoto Co., Inc. | Sulfur-containing amino acid-producing bacterium and method for producing sulfur-containing amino acid |
US9234223B2 (en) | 2011-04-01 | 2016-01-12 | Ajinomoto Co., Inc. | Method for producing L-cysteine |
Also Published As
Publication number | Publication date |
---|---|
EP1571223B1 (en) | 2010-01-20 |
EP1849874A1 (en) | 2007-10-31 |
JP4479283B2 (en) | 2010-06-09 |
JP2005245311A (en) | 2005-09-15 |
EP1571223A3 (en) | 2005-11-30 |
US20100093045A1 (en) | 2010-04-15 |
DE602005018981D1 (en) | 2010-03-11 |
EP1571223A2 (en) | 2005-09-07 |
DE602005021158D1 (en) | 2010-06-17 |
EP1849874B1 (en) | 2010-05-05 |
US8114649B2 (en) | 2012-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8114649B2 (en) | L-cysteine producing microorganism and a method for producing L-cysteine | |
US20090226982A1 (en) | L-cysteine producing microorganism and method for producing l-cysteine | |
US7611873B1 (en) | Method for producing L-methionine by fermentation | |
JP4186564B2 (en) | L-cysteine producing bacterium and method for producing L-cysteine | |
EP2695940B1 (en) | Method for producing l-cysteine | |
EP2486123B1 (en) | A METHOD FOR PRODUCING AN L-CYSTEINE, L-CYSTINE, A DERIVATIVE OR PRECURSOR THEREOF OR A MIXTURE THEREOF USING A BACTERIUM OF Enterobacteriaceae FAMILY | |
US20050124049A1 (en) | Method for producing L-cysteine using bacteria belonging to the genus Escherichia | |
US9234223B2 (en) | Method for producing L-cysteine | |
US20030049805A1 (en) | Fermentative production of L-lysine | |
US6946268B2 (en) | L-cysteine producing bacterium and method for producing L-cysteine | |
JP5803927B2 (en) | Sulfur-containing amino acid-producing bacteria and method for producing sulfur-containing amino acids | |
JP5579456B2 (en) | L-cysteine producing bacterium and method for producing L-cysteine | |
US11390896B2 (en) | Method for producing L-methionine using a bacterium of the genus Pantoea | |
EP2679680A1 (en) | L-cysteine-producing bacterium and method for producing l-cysteine | |
JP7444164B2 (en) | Method for producing L-methionine using bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AJINOMOTO CO., INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKAGI, HIROSHI;NAKAMORI, SHIGERU;WADA, MASARU;AND OTHERS;REEL/FRAME:016128/0930 Effective date: 20050607 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |